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More evidence is needed. Iron, incident cognitive decline and 
dementia: a systematic review 
Diane E. Hosking, Scott Ayton, Nigel Beckett, Andrew Booth and Ruth Peters 
 
Abstract 
Background: Our aim was to systematically review the relationship between iron 
and incident cognitive decline or dementia from midlife onwards. 
Methods: Systematic review of eligible studies using Medline, Embase and 
PsycINFO® for the period from 1 January 1986 to 2 December 2016 
(CRD42016023800), where study populations had a mean age of over 50 years and 
were free of cognitive impairment or dementia at baseline. Two authors 
independently extracted data according to eligibility criteria and assessed study 
characteristics, quality and outcomes. Disagreement was resolved by discussion. 
Results: A total of 1185 relevant records were identified with 12 full-text articles 
eligible for review. Six studies were excluded, leaving six texts to be included. Sample 
size ranged from 90 to 7173, with an average follow up of approximately 11.5 years. 
Baseline iron measures included brain iron (n = 2), iron-related biomarkers in blood 
and plasma (n = 2), and iron intake estimates from dietary records (n = 2). Outcomes 
were dementia incidence (n = 2) and longitudinal outcomes on neuropsychological 
tests (n = 4). Bias was evident across studies in one or more of the following: 
recruitment, iron exposure, outcome assessments, potential confounders, missing 
data or attrition. 
Conclusions: Diversity across the small number of identified studies precludes 
conclusions regarding the role of iron in cognitive decline or dementia. Our review 
highlights substantial gaps in the evidence base and the need for more 
comprehensive, higher quality studies in this area. 
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Introduction 
Older age is associated with increased risk of iron deficiency (ID), elevated body iron 
stores and increased brain iron levels.1,2 Complex regulatory mechanisms fine-tune 
iron metabolism and homeostasis for both heme and nonheme iron. 
 
Iron has a key role in multiple pathways, for example, as a constituent part of 
proteins needed for oxygen transport, oxidative phosphorylation, myelin production, 
and production and breakdown of neurotransmitters.35 Consequently there are 
multiple plausible mechanisms by which iron deficiency or overload may elevate the 
risk of age-related cognitive decline and dementia. A detailed mechanistic review is 
beyond the scope of this article, however for recent reviews in this area, see Hare 
and colleagues3 and Waldvogel- Abramowski and colleagues4 
Iron deficiency 
In older adults, absolute ID is caused by insufficient dietary iron intake, 
gastrointestinal malabsorption, or increased blood losses attributable to 
gastrointestinal pathologies.2 Potential cognitive impacts related to inadequate iron 
might stem from cerebral hypoxia,6 insufficient neurotransmitter synthesis5 or poor 
myelin integrity.7 
 
There is also a growing body of evidence that anaemia in older age (defined by 
haemoglobin level <13 g/dl in men and <12 g/dl in women) is associated with poor 
cognition, cognitive decline and dementia.8 ID anaemia accounts for around 16% of 
total anaemia cases.9 
Iron overload 
Body iron levels may be elevated in middle-aged and older adults due to consumption 
of highly bioavailable forms of iron (supplemental iron and red meat) and of fruit, an 
enhancer of nonhemeiron absorption (vitamin C).10 In two meta-analyses of 
prospective cohort studies, high body iron stores and consumption of heme iron 
were associated with increased risk of coronary heart disease (21 studies)11 and type 
2 (T2) diabetes (11 studies), 12 which may highlight a further pathway between iron 
overload and cognitive impairment and dementia.1315 
Increased brain iron 
The accumulation of iron in the brain is an established hallmark of ageing.16 Excess 
iron stores may increase pro-oxidant reactions and generation of free radicals,1,3 
which could contribute to neurodegeneration. In cross-sectional studies, 
magnetic resonance imaging (MRI) measures of iron are associated with amyloid 
load,17 smaller hippocampal volume18 and poorer cognitive performance.15,19 
Hippocampal iron content has also been correlated with cognitive performance 
Zg]]bl^Zl^]nkZmbhgbg:esa^bf^kl]bl^Zl^+)%+* and MRI-measured iron in the basal 
ganglia in cognitively normal adults predicted greater rates of cognitive decline and 
cortical atrophy.22,23 Brain iron deposits have also been positively associated with 
white matter hyperintensities, suggesting a potential link between brain iron and 
vascular pathology.15,24 
 
The proportion of the population at risk for cognitive decline and dementia is rapidly 
increasing, and there is no effective pharmacological cure or preventive intervention. 
The promotion of clinical understanding through collation of evidence for modifiable 
risk factors is an important preventive strategy. Iron has been raised as a potentially 
modifiable risk factor for cognitive decline or dementia but the area is complex. 
There are multiple ways of measuring both iron and cognition, and to date there is no 
critical appraisal of the evidence depth, breadth or quality. Our aim was to 
systematically review and evaluate the current evidence base that relates to the 
relationship between iron and incident cognitive decline or dementia. 
Methods 
Search strategy and selection criteria 
The databases MEDLINE, Embase and PsycINFO were searched over a 30-year period 
from 1986 to 2 December 2016. Because this is a first review of the literature in this 
area, search terms were chosen to be as broad as possible to prevent inadvertent 
exclusion of particular cognitive assessment or particular iron measures. 
 
Search terms included dementia, alzheimers disease, vascular dementia, multi-
infarct dementia, cognit* and iron, heme, haem, ferritin and serum transferrin. See 
supplementary text for details. Reference lists were screened and experts in the field 
were consulted. In addition, searches of the Cochrane Library, the ISRCTN Register 
and the ClinicalTrials.gov website were carried out to look for ongoing or completed 
relevant trials. 
 
All identified abstracts, or titles, where abstracts were unavailable, were 
independently read by two reviewers (DH, RP) and a list of potential evidence for 
inclusion was compiled by the two analysts (DH, RP). These lists were then compared 
and any differences resolved by discussion. Full text copies of the selected texts were 
independently read and assessed for relevance by both analysts and in accordance 
with the following inclusion and exclusion criteria. 
Inclusion criteria.  
Prospective longitudinal studies of primary research (cohorts or clinical trials) 
reporting on the following: 
1. An assessment of exposure to iron (assessed via biomarkers, e.g. blood, cerebral 
spinal fluid or neuroimaging) or external sources, for example, diet or iron 
supplementation. 
2. Evidence, or clear implication, that participants were free of cognitive decline or 
dementia at baseline assessment. 
3. Use of formal assessment of cognitive function. 
4. Reporting outcomes of cognitive decline or incident dementia. 
5. Adult populations with a mean age over 50 years 
Exclusion criteria: 
1. Publications relating only to populations selected on the basis of clinical 
comorbidity when that comorbidity may also affect cognitive function, for example, 
requirement for renal dialysis. 
2. Non English publications (in the absence of resources available for translation). 
3. Inclusion of nonadults. 
 
Papers identified as relevant were then independently assessed for quality and data 
relating to study characteristics, assessment of cognitive function and iron exposure 
were extracted by each analyst. A formal quality scoring scheme was not used as 
these lack discriminatory power, however each paper was assessed against the key 
factors given in Critical Appraisal Skills Programme checklists for evaluating trials 
and longitudinal studies (Critical Appraisal Skills Programme: http://www.casp-
uk.net/ accessed 15th February 2017). 
 
The review was carried out to best practice and in accordance with PRISMA 
guidelines.25 Protocol registration no. CRD42016023800. 
Results 
A total of 2001 records were identified from the searches and a further two from 
reference screening/expert recommendation; 1185 records 
remained once duplicates were removed. These were screened and 12 full text 
articles representing 12 separate studies were reviewed. Six studies were included 
with the remaining six excluded because they lacked results related to iron exposure 
(n = 2),26,27 included prevalent cases of cognitive impairment (n = 3),15,28,29 or had 
a cross-sectional design (n = 1).30 See Figure 1 for the PRISMA study flow chart. 
Study characteristics 
Of the studies that were included, four reported results from North American 
populations (United States of America); two using data from the National Health and 
Nutrition Examination Survey (NHANES),31,32 one from a Detroit-based cohort 
study,22 and one using participant ]ZmZ_khfma^:esa^bf^kl=bl^Zl^G^nkhbfZ`bg` 
Initiative (ADNI) cohort.33 The remaining studies were from Australia, a longitudinal 
cohort study based in Canberra and Queanbeyan,34 and the Netherlands, a cohort 
analysis of clinical trial data from the Folic Acid and Carotid Intima-Media Thickness 
(FACIT) trial.35 For further study characteristics, see Table 1. 
Measures of iron 
Studies used widely differing measures of baseline iron (Table 2). Of the six identified 
studies, two used measures of brain iron22,33 and four used measures of peripheral 
iron.31,32,34,35 The NHANES 40-plus cohort reported on serum transferrin,32 the 
NHANES 60-plus cohort and the Australian cohort study used dietary iron,34 
the FACIT trial collected total iron-binding capacity, transferrin saturation, ferritin 
and nontransferrin bound iron.35 Of those that collected data on brain iron, the ADNI 
cohort used ferritin in cerebrospinal fluid (CSF)33 and the Detroit study used 
imaging (MRI).22 The Detroit cohort and the FACIT trial cohort were the only studies 
to report assessment of iron at follow up. The FACIT trial collected serum iron, 
ferritin and nontransferrin bound iron and the Detroit study repeated their baseline 
MRI scan.22,35 
Cognitive outcome measures 
The NHANES cohorts reported on dementia outcomes (Table 3). Data on dementia 
and :esa^bf^kl]bl^Zl^hnm\hf^lp^k^\hee^\m^] from death certificates, hospital 
and nursing home records for the 40-plus cohort.32 Diagnoses h_:esa^bf^kl
disease for the 60-plus cohort were collected from death certificates only;31 ; neither 
carried out cognitive testing. The Detroit cohort,22 FACIT trial cohort,35 ADNI 
cohort33 and Australian cohort34 used standard cognitive assessment tools at 
baseline and follow up. 
Association between iron measures and cognitive outcomes as reported by the included 
studies 
Overall the results were variable across studies 
(Table 4): 
 
1. In the NHANES 40-plus cohort (n = 6427), an association was found between 
co-occurring high levels of transferrin (TS) and cholesterol, and increased risk of 
:esa^bf^kl]bl^Zl^T[hmaMLZg]\ahe^lm^khe at the 75th percentile, hazard ratio (HR) 
3.19, 95% confidence interval (CI) 1.317.75]; but no association between transferrin 
Zehg^Zg]:esa^bf^kl]bl^Zl^,+  (transferrin >75% compared with < 75% 
:esa^bf^kl]bl^Zl^3AK*'-0%2.<B 0.822.63). 
 
2. In the FACIT trial (n = 800) the potential of folic acid supplementation to modify 
the effects of iron measures on cognitive change was tested prior to examining 
associations between serum iron parameters and longitudinal cognitive functioning. 
No associations were found. When stratifying for status as a blood donor, higher iron 
status was associated with less decline in sensorimotor (parameter estimate = 0.005, 
p = 0.010) and word fluency tasks (parameter estimate = 0.006, p = 0.012).35 
 
3. The Australian PATH cohort study (n = 1354) found an increased risk of cognitive 
impairment with higher levels of iron intake (HR 1.54, 95% CI 1.032.29 for transition 
from normal cognition to mild cognitive impairment (MCI), per 1 mg iron) and the 
potential for an interaction with sex such that higher intake may be associated with 
lower risk in women but higher risk in men.3 
 
4. The PATH study reported a mean iron intake of 18 mg per day, more than double 
the daily intake of 8 mg recommended by the Australian National Health and Medical 
Research Council (NHMRC) for those in their sixties. 4. The Detroit cohort (n = 78) 
(examining the hippocampus, caudate and putamen) reported no association 
between baseline iron or change in iron and episodic memory or nonverbal working 
memory, with the exception of baseline iron in the caudate nucleus which was 
associated with less improvement in verbal working memory, ȕ 0.18 (p = 0.01).22 
5. The NHANES 60-plus cohort (n = 4639) _hng]ghZllh\bZmbhg[^mp^^g:esa^bf^kl 
disease related death and dietary iron intake (p = 0.1022) but an increased risk of 
:esa^bf^kl]bl^Zl^fhkmZebmrfound for those with low haemoglobin (HR 8.4, 95% 
CI 1.450.8).31 
 
6. The study using the ADNI cohort (n = 43) reported an increased risk of decline 
associated with higher levels of ferritin, but suggested that the result may be 
confined to those with the apolipoprotein (APOE) ڙ4 allele. For those who were 
APOE ڙ4 ihlbmbo^%:esa^bf^kl]bl^Zl^:ll^llf^gm Scale (ADAS Cog) ȕ 0.09 [standard 
error (SE) 0.04], p = 0.02, Rey Auditory Verbal Learning Test (RAVLT) ȕ 1.49 (SE 0.4), 
p < 0.001 compared with APOE ڙ4 negative, ADAS Cog ȕ 0.04 (SE 0.016), p = 
0.02, RAVLT nonsignificant.33 
 
 
 
Figure 1. Study selection flowchart. 
Source: http://prisma-statement.org/ 
Study quality 
All studies reported a clear research question (Table 5). However, studies utilized 
diverse designs with the potential for bias in recruitment, measures of iron exposure, 
outcome assessment, potential confounders, missing data or attrition. 
 
The applicability of three studies was limited by recruitment from specific population 
groups; one from an ongoing longitudinal study of ageing,22 one from the ongoing 
ADNI study33 and one from a clinical trial population.35 The other three studies used 
representative population samples from Australia34 and the USA.31,32 However, 
Mainous and colleagues32 (n = 6427) selected a cohort aged from 40 years upwards, 
thus potentially minimizing the potential to observe meaningful cognitive change. 
Four of the studies reported on populations with a mean age over 60 years, that is 
those more likely to manifest cognitive change,31, 3335 and recruited large numbers 
(NHANES 60 n = 4639, PATH N = 1354, FACIT n = 800), with the exception of the ADNI 
study (n = 43). None focused solely on older adults and one, the Daugherty imaging 
study, included a wide age range from 19 to 77 years (n = 78), which would have 
included a varied population; in particular, pre- and postmenopausal women.22 
Furthermore, full details of statistical methods and adjustment for potential 
confounders was limited and inconsistent, and three studies lacked adequate 
adjustment for the confounding variables likely to influence cognitive 
function.22,31,32 
 
The measurement of iron was similarly varied. None of the studies attempted to take 
account of prior iron exposure and iron status at follow up was assessed only in the 
FACIT trial35 and the Detroit Aging study.22 Exposure measures were selective, with 
no overlap and no combined dietary and biomarker assessments. Only two studies 
measured brain iron levels.22,33 
 
Measurement of cognitive function was also limited, both in breadth and sensitivity. 
Outcome assessments were selected from standard test batteries for four of the 
studies. 3336 The two studies using the NHANES database collected outcome data 
from death certificates31,32 and healthcare records,32 thus raising the possibility of 
misclassification and under reporting due to missed cases in the community, lack of 
high-quality diagnoses in nursing home environments and less than rigorous death 
certificate coding. 
 
The interpretation of study results is also limited by the varying research questions 
and statistical focus in the different studies. For example, the publication by Mainous 
and colleagues aimed to look at cholesterol in combination with transferrin rather 
than using iron measures alone,32 and the publication by Min and colleagues focused 
on haemoglobin, folate and vitamin B12, reporting on iron only in passing as a 
covariate and as part of the baseline 
 
 
Table 1. Study characteristics. 
Author 
and 
study 
Design  Participants 
and setting 
Baseline 
n 
Follow 
up n 
Follow-
up 
years 
Reason 
losses 
to 
follow 
up 
Baseline 
age or 
mean 
(SD) 
Baseline% 
female 
Mainous 
et al.32 
NHANES 
40 
 
Longitudinal 
cohort 
study 
The National 
Health and 
Nutritional 
Examination 
Survey 
(NHANES 
survey): USA 
      
Schiepers 
et al.35 
FACIT 
 
Longitudinal 
cohort 
study 
 
The Folic Acid 
and 
Carotid 
Intima- 
Media 
Thickness 
(FACIT) Trial: 
The 
Netherlands 
 
      
Cherbuin 
et al.34 
PATH 
 
Longitudinal 
cohort 
study 
The PATH 
through Life 
study: 
Canberra, 
Australia 
      
Daugherty 
et al.22 
DETROIT 
 
Longitudinal 
cohort 
study 
Detroit 
cohort 
study: 
Detroit, USA 
      
Min et 
al.31 
NHANES 
60 
Longitudinal 
cohort 
study 
NHANES 
survey 
linked to 
mortality 
data (1999
2006): 
USA 
      
Ayton et 
al.33 
ADNI 
Longitudinal 
cohort 
study 
The 
:esa^bf^kl 
Disease 
Neuroimaging 
Initiative 
(ADNI) 
cohort: USA 
      
         
6558 6427 18 No 40+ ~ 4563% 
across 
measures 
 
818 800 3 Yes Mean 
60.3 (5.6) 
28.4% 
 
2096 1354 8 Yes 6064 
Mean 
62.54 
(1.53) 
51.7% 
 
 
 
125 78 2 Yes 1977 
Mean 
52.53 
(14.91) 
70% 
 
4688 4639 512 N/A: loss 
due to 
mortality 
6089 51% 
 
90 43 7 No Mean 
75.7 (5.5) 
51% 
N/A, not applicable. 
 
Table 2. Measurements of iron. 
Author  Peripheral or brain iron 
measures 
Measure of iron at 
baseline  
Measure of iron at 
follow up 
Mainous et al.32 
NHANES 40 
 
Peripheral Serum transferrin N/A 
 
Schiepers et al.35 
FACIT 
 
Peripheral Total serum iron, serum 
concentration of 
transferrin*, 
Transferrin saturation$, 
l^knf_^kkbmbg¨%
nontransferrin-bound 
iron§ 
Same as baseline 
with the exception of 
nontransferrin-bound 
iron 
Cherbuin et al.34 
PATH 
Peripheral Dietary iron calculated from the Commonwealth Scientific 
Industrial Research Organisation (CSIRO FFQ) 
N/A 
Daugherty et al.22 
DETROIT 
Brain In vivo estimation with MRI adds regions of interest 
hippocampus, caudate and putamen 
In vivo estimation with MRI 
Min et al.31 
NHANES 60 
Peripheral Dietary iron (calculated from 24 h recall) N/A 
Ayton et al.33 
ADNI 
Brain Ferritin in cerebrospinal fluid N/A 
*Transferrin: iron transport protein. 
$Transferrin saturation: the ratio of serum iron to serum concentration of transferrin. 
¨Ferritin: indicator of total body iron stores. 
§Nontransferrin-bound iron: free iron in the circulation not bound to transferrin. 
MRI, magnetic resonance imaging; N/A, not applicable; FFQ, food frequency questionnaire. 
DE Hosking, S Ayton et al. 
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characteristics.31 None of the studies focused on 
a potential U-shaped relationship with iron and 
cognitive outcome. Participant numbers, and subsequently the numbers per cell in 
analyses were also particularly small in some studies; in 
the study by Min and colleagues only 49 participants 
_khf-/11aZ]]b^]_khf:esa^bf^kl]bl^Zl^ at follow up.31 Daugherty included only 
125 participants22 and in the study by Ayton 
and colleagues there were only 90 participants 
in the cognitively normal group.33 Finally, participant 
dropout and missing data31,34 further 
limit the interpretation of the results. 
Discussion 
To our knowledge, this is the first systematic review of the evidence relating to iron, 
cognitive decline and dementia. Overall, the available studies were inconsistent in 
terms of length of follow up, composition of study population, percentage 
female or male, age of study sample, iron assessment, outcome measure and results. 
Two studies assessed the influence of dietary iron in relatively similar age groups, 
one (the USA NHANES 60-plus cohort31) found no association with dementia. The 
other (the Australian PATH study34) found an increased risk of cognitive 
Table 3. Measurement of cognitive function. 
Author Baseline assessment 
cognitive function 
Follow-up assessment cognitive function 
Mainous et al.32 
NHANES 40 
N/A N/A 
Schiepers et al.35 
FACIT 
Five cognitive domains assessed. Domains 
constructed by using either the average of 
individual test z scores or for two constructs, single 
tests only 
Memory (visual word learning test; immediate 
recall, maximal immediate recall, delayed recall) 
L^glhkbfhmhkli^^]!\hg\^imlab_mbg`m^lml^fimr% 
e^mm^kl%gnf[^kl%\hehnkLmkhhi%k^Z]bg`phk]l" 
<hfie^qli^^]!\hg\^imlab_mbg`%e^mm^kl 
gnf[^kl%\hehnkLmkhhi%gZfbg`bgd" 
Information processing speed (letter digit 
substitution test) 
Verbal fluency (verbal fluency test) 
Five cognitive domains assessed. Domains 
constructed by using either the average of individual 
test z scores or for two constructs, single tests only 
Memory (visual word learning test; immediate 
recall, maximal immediate recall, delayed recall) 
L^glhkbfhmhkli^^]!\hg\^imlab_mbg`m^lml%^fimr% 
e^mm^kl%gnf[^kl% \hehnkLmkhhi%k^Z]bg`phk]l" 
<hfie^qli^^]!\hg\^imlab_mbg`%e^mm^kl 
gnf[^kl%\hehnkLmkhhi%gZfbg`bgd" 
Information processing speed (letter digit 
substitution test) 
Verbal fluency (verbal fluency test) 
Cherbuin et al.34 
PATH 
Participants were selected for clinical assessment 
if they had any of the following: a MMSE cutoff 乘25, 
a score below 5th percentile on the CVLT, on SDMT 
or the Purdue pegboard with both hands or RT 
Clinical assessment included neuropsychological 
testing using the following: trials A&B; clock 
drawing; Boston naming task; constructional 
praxis (CERAD); the RAVLT, recall of constructional 
praxis for nonverbal memory 
Participants were selected for clinical assessment if 
they had any of the following: a MMSE cutoff 乘25, a 
score below 5th percentile on the CVLT, on SDMT or 
the Purdue pegboard with both hands or RT 
Clinical assessment included neuropsychological 
testing using the following: trials A&B; clock 
drawing; Boston naming task; constructional praxis 
(CERAD); the RAVLT, recall of constructional praxis 
for non-verbal memory 
Daugherty et al.22 
DETROIT 
Latent cognitive constructs were tested for: 
working memory (listening span, verbal N-back 
task), nonverbal working memory (spatial recall, 
visual N-back tasks), episodic memory (logical 
memory subset of the Wechsler memory scales 
revised) 
Latent cognitive constructs were tested for: working 
memory (listening span, verbal N-back task), 
nonverbal working memory (spatial recall, visual 
N-back tasks), episodic memory (logical memory 
subset of the Wechsler memory scales revised) 
Min et al.31 
NHANES 60 
N/A N/A 
Ayton et al.33 
ADNI 
The ADAS Cog, RAVLT ADAS Cog, RAVLT 
:=:L<h`%:esa^bf^kl]bl^Zl^:ll^llf^gmL\Ze^4<>K:=%<hglhkmbnfmh>lmZ[eblaZK^`blmkr_hk:esa^bf^kl]bl^Zl^4 CVLT, 
California Verbal 
Learning Test; N/A, not applicable; RAVLT, Rey Auditory Verbal Learning Test; RT, reaction time; SDMT, Digit Symbol Modalities 
Test; 
MMSE, mini-mental state exam. 
Therapeutic Advances in Chronic Disease 00(0) 
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Table 4. Results reported by included studies. 
Author N Results Additional comment Confounders 
Mainous et al.32 
NHANES 40 
6427 Unadjusted (transferrin alone) transferrin 
>75% compared with <75% 
Dementia HR 1.11 (95% CI 0.791.56) 
AD HR 1.47 (95% CI 0.822.63) 
High cholesterol and high transferrin saturation levels 
consistently had the highest risk of developing AD 
compared with the reference group (low cholesterol and 
low transferrin). Having only high cholesterol or only high 
transferrin did not increase risk for AD. Unadjusted relative 
risk of developing AD when both TS and cholesterol were at 
the 75th percentile was 3.19 (95% CI 1.317.75). In adjusted 
models when only one marker was elevated, there was no 
significant increased risk for AD. The risk of AD increased as 
both markers increased 
Age, sex, race, 
education, BMI, 
exercise, diabetes, 
hypertension, vitamin 
C level 
Schiepers et al.35 
FACIT 
800 When analyses were stratified by blood 
donor status, higher serum iron predicted 
less decline in nondonors in sensorimotor 
speed (parameter estimate = 0.005, 
p = 0.010) in word fluency (parameter 
estimate = 0.006, p = 0.012) 
Cognitive performance declined over 3 years for 
sensorimotor speed, complex speed and information 
processing. Memory improved and word fluency did not 
change. Ferritin concentrations increased significantly 
but serum iron decreased, although not significantly. No 
significant longitudinal associations were found between 
any of the iron parameters and cognitive functioning. The 
HFEC28Y mutation (produces elevated iron levels) was not 
associated with cross-sectional or longitudinal cognitive 
performance, indicating lifelong exposure to elevated iron 
does not affect cognitive function in later life. The potential 
effect modification by treatment with folic acid in the 
trial was assessed prior to longitudinal analyses and no 
interaction between folic acid supplementation and iron 
status was found. All subsequent analyses were adjusted for 
covariates 
Age, sex, education 
(formal schooling), 
alcohol consumption, 
current smoking, 
BMI, physical activity, 
apolipoprotein E, 
genotype C-reactive 
protein, haemoglobin, 
blood donor status, 
group status (for folic 
acid treatment) 
Cherbuin et al.34 
PATH 
1354 For each 1 mg increase in iron at baseline, 
risk of MCI but not MCD increased over 8 
years of follow up 
For transition from normal cognition to 
MCI, HR 1.54 (95% CI 1.032.29), p = 0.03 
For transition from normal cognition to 
MCD, HR 1.10 (95% CI 0.871.37), p = 
0.418. 
Unadjusted 
For each 1 mg increase in iron at baseline the risk of MCI 
but not MCD increased over 8 years 
For transition from normal cognition to MCI, HR 1.50 (95% CI 
1.072.10), p = 0.019 
For transition from normal cognition to MCD, HR 1.05 (95% 
CI 0.951.16), p = 0.309 
Trend towards sex interaction such that higher iron intake 
associated with decreased risk of MCI incidence in women, 
HR 0.81 (95% CI 0.611.07), p =0.144) and increased risk of 
MCI incidence in men, HR 1.08 (95% CI 0.941.18), p =0.287 
age, sex education, 
alcohol intake, smoking, 
BMI, stroke, diabetes, 
hypertension (including 
medication use) APOE 
ڙ 4status depressive 
symptoms physical 
activity 
DE Hosking, S Ayton et al. 
journals.sagepub.com/home/taj 9 
Author N Results Additional comment Confounders 
Daugherty et al.22 
DETROIT 
78 Higher baseline iron in the caudate 
nucleus was associated with less 
improvement in working memory, ȕ 0.18 
(p = 0.01) 
No association between putamen or hippocampal baseline 
iron or change in iron with working memory. No association 
between brain iron at baseline or change in brain iron and 
episodic memory 
Age and sex retained in 
final models 
Min et al.31 
NHANES 60 
4639 Increased risk of AD mortality found for 
those with low haemoglobin (HR 8.4, 95% 
CI 1.450.8) 
There were 49 AD-related deaths at follow up. No 
relationship between AD death and dietary iron intake, but 
those with AD mortality had significantly lower haemoglobin 
levels. Those who had AD had lower haemoglobin (14.0g/dl 
compared with 14.1g/dl, p = 0.0089 t test). 
Significant reduction in AD mortality risk with increases in 
haemoglobin for those with low levels of both folate and 
vitamin B12 
Age, sex, ethnicity, 
education, smoking 
history, BMI, diabetes 
or hypertension, dietary 
intake of iron 
Ayton et al.33 
ADNI 
43 Baseline ferritin was associated 
with cognitive decline in a three-way 
interaction with time and presence of 
APOE ڙ4 
ADAS Cog ȕ 0.11 (SE 0.04), p = 0.01 
RAVLT ȕ 1.58 (SE 0.54), p = 0.004 
Examined by presence of APOE ڙ4 
APOE ڙ4 positive: 
ADAS Cog ȕ 0.09 (SE 0.04), p = 0.02 
RAVLT ȕ 1.49 (SE 0.4), p < 0.001 
APOE ڙ4 negative: 
ADAS Cog ȕ 0.04 (SE 0.016), p = 0.02 
RAVLT NS 
All models included sex and years of education. The 
covariates CSF APOE, factor H and haemoglobin were not 
predictive in any models. No unadjusted results. Models 
initially included all covariates before minimal models were 
obtained empirically via empirical testing of model fit 
Age, sex, BMI, 
education, CSF tau/ 
amyloid ȕ, CSF APOE, 
CSF ferritin, CSF 
factor H (a measure of 
inflammation) 
AD, Alzheimekl]bl^Zl^4:=:L<h`%:esa^bf^kl]bl^Zl^:ll^llf^gmL\Ze^4:IH>%Zihebihikhm^bg>4;FB%[h]rfZllbg]^q4<B%
confidence interval; CSF, cerebrospinal fluid; HR, hazard 
ratio; NS, nonsignificant; RAVLT, RAVLT, Rey Auditory Verbal Learning Test; SE, standard error; MCD, mild cognitive disorders; 
MCI, mild cognitive impairment. 
Table 4. (Continued) 
 
 
Table 5. Assessment of study quality. 
Author  
Recruitment bias  
Exposure bias  
Bias in outcome measurement 
Bias in assessment of confounders 
Bias in follow up, patient loss 
Bias in follow up, length 
Overall quality assessment 
Mainous 
et al.32 
NHANES 
40 
Moderate. NHANES 
was designed to be 
representative of 
the US population 
with additional 
oversampling of key 
population subgroups 
including those aged 
65 and over. However, 
baseline included 
those in midlife 
(40 years+) which 
limits opportunity to 
detect association 
between exposure and 
dementia incidence 
over 20 years 
Moderate. Baseline 
measures only and 
longer term exposure 
not considered 
Moderate. Dementia/ 
AD measured through 
health, hospital and 
nursing home records 
plus death certificates. 
Misclassification 
possible and cases 
living in the community 
may have been 
overlooked 
Moderate. Multiple 
key confounders 
are included 
but assessment 
methods were 
not noted except 
for vitamin C 
usual intake 
not necessarily 
captured by 24 h 
dietary history 
Low. 98% 
follow-up rate 
for NHANES. 
Follow-up 
data collected 
by interview 
or proxy if 
participant 
unable to 
respond or 
deceased 
Moderate. 
Potential 
for some 
participants 
to have 
contributed 
fairly short 
follow up 
meaning 
reverse 
causality 
cannot be 
excluded 
Moderate 
Schiepers 
et al.35 
FACIT 
High. Not a 
representative sample 
(54% blood donors). 
Participants had to 
meet clinical trial 
inclusion criteria, 
e.g. a plasma total 
homocysteine 亂13 
and 乘26 ȝmol/liter; 
50% also received folic 
acid supplementation 
Moderate. Baseline 
and follow-up 
measures are 
used but longer 
term exposure not 
considered 
Moderate. Cognitive 
tests from a 
neuropsychological 
battery were combined 
into researcher 
defined composite 
domain scores rather 
than taking a datadriven 
factor analytic 
approach to determine 
the underlying 
constructs assessed 
Low. Multiple key 
confounders are 
included. BMI 
was specified as 
calculated through 
height and weight 
but not clear if this 
was measured 
objectively or by 
self report 
Low. Minimal 
loss to follow 
up 
Moderate. 
Reverse 
causality 
possible in 
2-year follow 
up 
Moderate 
 
Author  Recruitment 
bias  
Exposure 
bias  
Bias in 
outcome 
measurement 
Bias in 
assessment 
of 
confounders 
Bias in 
follow 
up, 
patient 
Bias in 
follow 
up, 
length 
Overall 
quality 
assessment 
loss 
Cherbuin 
et al.34 
PATH 
Low. Recruitment of 
a random selection 
from the electoral 
role membership of 
which is mandatory in 
Australia 
Moderate. Baseline 
measures only and 
longer term exposure 
not considered and 
those with missing 
data were excluded. 
Iron status assessed 
through self-report 
FFQ which does not 
have the reliability of 
serum markers for 
iron status 
Moderate. 
Neuropsychological 
battery and clinical 
assessment of 
dementia used to 
assess cognitive 
function but those with 
missing data were 
excluded 
Moderate. Key 
confounders 
are included 
but those with 
missing data were 
excluded. BMI was 
calculated using 
self-report height 
and weight 
Moderate. 
There were 
2551 recruited 
and 1275 
included after 
exclusion of 
missing data 
etc. 
Moderate. 
Follow up is 
sufficient to 
detect incident 
change, 
however 
exclusion of 
those with 
missing data 
may have 
caused bias 
Moderate 
Daugherty 
et al.22 
DETROIT 
Moderate. 
Recruitment was 
part of an ongoing 
longitudinal study of 
ageing 
Moderate. Baseline 
and follow-up 
measures are 
used but longer 
term exposure not 
considered 
Moderate. Working 
and episodic memory 
measures were 
taken from a larger 
neuropsychological 
battery assessment. 
No theoretical 
justification was 
given as to why these 
measures were chosen 
Moderate A 
selection of key 
confounding 
variables were 
included. In 
particular, 
time-varying 
confounders were 
measured by 
objective blood 
markers and 
included in the 
model as a latent 
metabolic factor, 
thereby excluding 
variable-specific 
error 
High; ~37% of 
sample lost to 
follow up 
Moderate. 
Reverse 
causality 
possible in 
2-year follow 
up, however 
reverse effects 
models were 
empirically 
tested 
Moderate 
Table 5. (Continued) 
(Continued) 
Author  Recruitment 
bias  
Exposure 
bias  
Bias in 
outcome 
measurement 
Bias in 
assessment 
of 
confounders 
Bias in 
follow 
up, 
patient 
loss 
Bias in 
follow 
up, 
length 
Overall 
quality 
assessment 
Min et al.31 
NHANES 
60 
Low. NHANES was 
designed to be 
representative of 
the US population 
with additional 
oversampling of key 
population subgroups 
including those aged 
65 and over 
Moderate. Baseline 
measures only and 
longer term exposure 
not considered. 
Measurement 
methods for dietary 
iron not clear 
Moderate. Death 
certificate data may 
not be accurate or 
complete. At follow 
up those without 
AD mortality may 
nonetheless have had 
AD 
High. Insufficient 
details of analysis 
methods for 
iron to allow 
evaluation. Small 
cell sizes for each 
iron quartiles in 
subjects with AD 
mortality 
Moderate. 
Those without 
measures of 
haemoglobin, 
or red-cell 
folate/B12 
and those 
with any other 
missing data 
were excluded 
Moderate. 
Potential 
for some 
participants 
to have 
contributed 
fairly short 
follow up, 
meaning 
reverse 
causality 
cannot be 
exclude 
Moderate 
Ayton 
et al.33 
ADNI 
Moderate. Selection 
was from the mild 
cognitive impairment 
and control groups 
h_ma^:esa^bf^kl 
Disease Neuroimaging 
Initiative (ADNI) data 
sets. ADNI recruited 
from multiple sites 
across North America 
Moderate. Baseline 
measures only and 
longer term exposure 
not considered 
Moderate. A standard 
neuropsychological 
test and cognitive 
screening test 
were used and data 
collected annually. 
However, the ADAS 
Cog (screening test) 
may not be a sensitive 
measure of cognitive 
change in those who 
are cognitively normal. 
Some bias may also 
have been possible as 
participant data were 
included until death or 
loss to follow up 
Low. Key 
confounders 
including a 
measure of 
inflammation 
Moderate. 
However, all 
participants 
were included 
until loss 
Moderate. 
Some 
participants 
left the study 
prior to the end 
of the 7-year 
follow up, 
however overall 
follow up was 
long enough 
to measure 
change in 
cognitive 
function 
Moderate 
:=%:esa^bf^kl]bl^Zl^4:=:L<h`%:esa^bf^kl]bl^Zl^:ll^llf^gmL\Ze^4;FB%[h]rfZllbg]^q4GA:G>L%GZmbhgZeA^ZemaZg]
Nutrition Examination Survey; FFQ, food frequency 
questionnaire. 
Table 5. (Continued) 
 
decline associated with greater iron intake, possibly 
more relevant in men. 
Several of the studies did report a stronger relationship 
in a particular subgroup, although the 
subgroups also varied. The older NHANES 
cohort found a relationship between higher transferrin 
Zg]bg\k^Zl^]kbldh_:esa^bf^kl]bl^Zl^bg 
those with higher cholesterol.32 In the ADNI 
cohort the relationship between higher cerebrospinal 
ferritin and cognitive decline was strongest 
in those who were also APOE ڙ4 positive,33 and 
in the FACIT trial cohort, higher serum iron levels were associated with less decline in 
sensorimotor speed and word fluency in those who did not donate blood.35 
 
A recent comprehensive review of iron deficiency and risk of cardiovascular disease 
included 13 longitudinal studies of serum iron, 15 studies of ferritin and 14 of 
transferrin saturation and total iron binding capacity, but also observed 
heterogeneity and inconclusive findings across studies. Although they concluded that 
^qmk^f^\hg]bmbhgl of iron deficiency as well as iron overload were associated with 
increased cardiovascular disease kbld',0 
 
Limitations associated with our review and its conclusions stem mostly from the 
paucity of studies rather than the methods used for the review process. It is possible 
that in restricting the language to English and in excluding study populations 
with serious clinical comorbidities, potentially relevant evidence has been 
overlooked. However, including populations with specific comorbidities where the 
comorbidity itself may influence iron metabolism, risk of mortality and 
risk of cognitive decline would have been to address a different research question. 
The lack of evidence, and the varying study designs and populations used within the 
available evidence base, present a more serious limitation. 
Limitations in the assessment of iron 
None of the studies used a fully comprehensive assessment of iron status. This is 
important because cerebrospinal fluid and blood reporters of iron only have a 
modest association,29 blood iron markers do not predict MRI measured brain iron 
content38 and, in older adults in particular, levels of the peripheral iron reporters, 
ferritin and haemoglobin, may also signify peripheral inflammation such as anaemia 
of chronic inflammation,39 or indeed noniron-deficient anaemia. In the case of the 
latter, tissue deposition of iron may occur even when presenting with low iron 
markers in the blood.  
 
For example, the iron-trafficking disease, aceruloplasminemia, results in tissue iron 
deposition and lower blood iron markers because iron cannot efficiently be exported 
out of the cell.40 If cellular iron trafficking, rather than iron exposure, is the lesion 
that results in brain iron elevation in :esa^bf^kl]bl^Zl^%bmblihllb[e^maZm]^ie^mbhg
of iron in the blood accompanies iron elevation in tissues. Furthermore, only two of 
the studies assessed dietary iron and no studies evaluated the impact of iron 
supplementation. No studies directly followed a potential link between iron intake 
and iron blood or neuroimaging biomarkers and subsequent cognitive function, and 
none attempted to evaluate iron impact by baseline iron level or by clinically relevant 
categories such as iron deficiency anaemia or iron deficiency no anaemia. We were 
unable to identify any trials of dietary iron exposure, or of iron supplementation, in 
normal or iron-deficient adults in mid or late life and risk of cognitive decline. 
Limitations in the assessment of outcome 
Cognition is complex and multifaceted and it is possible that iron status differentially 
affects change or decline across the spectrum of ability domains. Clearly, in the 
cognitively healthy a more comprehensive and psychometrically driven approach to 
assessing cognitive change is necessary if the impact of iron status on cognitive 
decline is to be more fully understood. The use of medical and death certificate 
records for dementia diagnoses in the NHANES analyses presents a further limitation 
since their accuracy depends upon robust and comprehensive assessment and 
record keeping. 
Gaps in the evidence base and future work 
Our systematic review of the current evidence base relating to iron and cognitive 
function and dementia found a sparse and limited field of evidence. 
 
Much more work is needed to evaluate the links between iron intake, brain 
deposition, ageing and cognitive function over time. In particular, a detailed focus is 
needed on regional brain iron and related cognitive abilities with multiple follow ups, 
MRI measures or historical health measures taking closer account of potential causal 
and associative relationships, including key confounding measures. Obvious examples 
include ensuring that analyses with ferritin (also an acute phase protein) are, at 
minimum, adjusted for other inflammatory markers, and taking account of obesity 
and its association with iron dysregulation. 
 
Multimodal approaches should also be used, such as using CSF iron biomarkers in 
combination with MRI measures of brain iron. Larger, longer and more thorough 
epidemiological studies are also needed to fully explore the potential pathways as is a 
greater emphasis on collection of biomarkers to allow more accurate evaluation of 
the homeostatic iron picture in its entirety, taking account of the varied iron types 
and storage mechanisms. 
 
This would also be an important part of the safety considerations prior to conducting 
any randomized clinical trials of iron supplementation or iron chelation. In particular, 
we recommend that future studies in this area focus on reducing risk of bias derived 
from varied participant populations; that is, select those of a particular age range and 
stratify by sex. Studies should collect at least two measures of cognitive function over 
a minimum follow up of 12 months to allow assessment of change; when possible, two 
matching iron measures should be taken at the same interval, ideally using imaging 
and linking region of interest to the cognitive domain under assessment. This should 
be supplemented by peripheral measures, including inflammatory markers; when 
possible, additional data on usual diet, and clinical and cardiovascular history should 
be obtained. 
Conclusion 
The current evidence base is sparse and limited. The diversity of the existing 
evidence limits interpretation and applicability by either healthcare providers or 
researchers and precludes any conclusion relating to the relationship between iron 
and cognition. Much more work is needed before we can develop our understanding 
of the role of iron in cognitive function. 
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